ArticleFrontiers in oncology2026
Spectral discrimination of pediatric SF188 and adult glioblastoma stem cells by deep learning-enhanced Raman profiling.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pediatric and adult glioblastomas (GBM) represent biologically distinct entities requiring age-tailored therapeutic strategies. However, rapid and non-invasive methods to distinguish these molecular subtypes remain an unmet clinical need. This study evaluates the potential of confocal Raman spectroscopy combined with deep learning as a label-free diagnostic tool to differentiate pediatric from adult GBM based on intrinsic biochemical fingerprints. Methods: We acquired n=1,382 Raman spectra from a cohort of six patient-derived GBM neurosphere cell lines, comprising a pediatric model (SF188) and five adult-origin lines. A multilayer perceptron (MLP) neural network was trained to classify spectra by age group. To ensure rigorous validation and generalizability, performance was assessed on a strictly held-out external test set (20% of data), completely excluded from model optimization. Results: The deep learning model successfully differentiated pediatric from adult GBM signatures with an overall accuracy of 83.6% and an ROC AUC of 0.855 on the independent test set. Spectral analysis revealed distinct vibrational modes, highlighting significant variations in lipid, protein, and nucleic acid content between age groups. Notably, the model achieved a high sensitivity for the pediatric phenotype (91.4% identification rate) . Conclusion: This proof-of-concept study demonstrates that Raman spectroscopy, augmented by deep learning, can identify age-related molecular variations in GBM without extrinsic labeling. By capturing the unique biochemical landscape of pediatric versus adult tumors, this approach lays the foundation for rapid, automated, and objective diagnostic workflows in precision neuro-oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.